Blueprint Medicines Corp

Sanofi has acquired Blueprint Medicines Corporation for $9.1 billion, expanding its portfolio in rare immunological diseases and early-stage immunology pipeline.

Sanofi has acquired Blueprint Medicines Corp for $9.1 billion, expanding its oncology and immunology portfolios and providing a lifeline to BPMC’s innovative cancer treatments.

Sanofi has acquired Blueprint Medicines Corp for approximately $9.1 billion, expanding its portfolio in oncology and rare immunological diseases.

Sanofi has acquired Blueprint Medicines Corporation in a $9.5 billion deal, expanding its presence in the rare immunology disease market and adding promising pipeline assets.